Erasca

Leap Therapeutics has announced a significant restructuring, reducing its workforce by approximately 50% and narrowing the development focus of its lead cancer drug candidate in response to challenging market conditions.

A retrospective analysis of 1,070 gynecologic cancer patients shows elderly and frail individuals experience worse postoperative outcomes despite following enhanced recovery protocols.

• Erasca's Naporafenib, combined with trametinib, demonstrates potential for durable efficacy in NRAS-mutant melanoma, addressing a critical unmet need after frontline immunotherapy. • Phase 1b SEACRAFT-1 trial data supports a tissue-specific approach, reducing dermatologic toxicities through mandatory primary prophylaxis, reinforcing the ongoing Phase 3 SEACRAFT-2 trial. • Erasca's RAS targeting franchise, including ERAS-0015 and ERAS-4001, progresses rapidly with planned IND submissions on track for early 2025, expanding treatment options for RAS/MAPK pathway-driven cancers.

• Erasca's naporafenib plus trametinib demonstrates a 40% response rate in NRAS-mutant melanoma patients in the Phase 1b SEACRAFT-1 trial. • The Phase 3 SEACRAFT-2 trial is progressing with randomized data expected in 2025, supported by regulatory alignment in the US and Europe. • Erasca's RAS targeting franchise, including ERAS-0015 and ERAS-4001, is on track for IND submissions in H1 2025 and Q1 2025, respectively. • The treatment shows favorable tolerability with mostly low-grade adverse events, improved by mandatory primary prophylaxis for dermatological toxicities.